Ensign Peak Advisors’s NovoCure NVCR Stock Holding History
Bought
Maintained
Sold
Other funds holding NVCR
SCM
VPM
VCM
QCM
Ensign Peak Advisors's NVCR Position: Q1 2026 in Review
Ensign Peak Advisors held its NovoCure (NVCR) position steady in Q1 2026 at 6,737 shares worth $73.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1628.
Ensign Peak Advisors first reported a position in NVCR in Q2 2021 and has held it in 20 quarters since. The position peaked at $2.38M in Q4 2021. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.
- Ensign Peak Advisors held 6,737 shares of NovoCure worth $73.4K as of Q1 2026.
- Ensign Peak Advisors left its NovoCure share count unchanged in Q1 2026.
- NovoCure made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q1 2026, its #1628 holding.
- Ensign Peak Advisors first reported a position in NovoCure in Q2 2021 and has held it in 20 quarters since.
- Ensign Peak Advisors's NovoCure position peaked at $2.38M in Q4 2021.
- 222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.
Based on Ensign Peak Advisors's 13F filing for Q1 2026, filed 13 May 2026.